Corporate VC Backing Influences Private M&A Step-Ups
This article was originally published in Start Up
Executive Summary
New data show that including one or more corporate venture investors in a syndicate actually translates into a higher median step-up valuation.
You may also be interested in...
Corporate Venture "Parents" Rarely Buy Or Partner With Biotech Investments
Based on a five-year analysis of the biopharma investments of SR One, Novartis Venture Funds, and Johnson & Johnson Development Corp., the "parent" entities of these CVC arms rarely, if ever, forge partnerships with their biotech portfolios.
Corporate Investors Boost M&A Step-Ups, But Not IPOs
Corporate venture capital groups have made an impact on life science investing in recent years, but when it comes to going public, the biotechs they back aren’t seeing an extra boost.
Financings Of The Fortnight Ponders The Meaning Of The Best Year For Biotech IPOs Since 2007
Plus news on recent financings by Regulus, Aragon, Antabio and Asceneuron.